Gain Therapeutics Presents Positive Preclinical Data on its Small Molecule Lead Compound in GBA1 Parkinson's Disease at XXVII IAPRD World Congress
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Stay updated with breaking news from Silverstein Foundation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
BETHESDA, Md., Feb. 04, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming...
Data Show Statistically Significant Increases in GALC Enzyme and Depletion of Toxic Substrate Psychosine...
Q&A: How DNA detective work is helping crack complex diseases 6 May, 2021 01:30 AM 6 minutes to read Recent breakthroughs in genetics have transformed our understanding of many complex diseases. Image / 123RF The human genetic code is mind-bogglingly complex - but it's a field of science Professor Justin O'Sullivan feels at home in. The deputy director of the University of Auckland's Liggins Institute, and a fellow of the Office of the Prime Minister's Chief Science Advisor, will be giving his inaugural professorial lecture tomorrow afternoon about genetics, complex diseases and the...
Compounds reverse the neurodegenerative process observed in a Parkinson’s disease in vivo model Compounds are novel allosteric regulators that bind, stabilize and restore activity of mutated GCase Compounds decrease both phosphorylated and aggregated α -synuclein levels in vitro and in vivo BETHESDA, Md., May 03, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (NASDAQ: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by using super-computational methods to target allosteric binding sites and guide enzymes back to their proper shape, today announced new pr...